
News|Articles|August 1, 2005
Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits
Phase 3 clinical trial results have demonstrated that the dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist muraglitazar achieves significant beneficial lipid effects compared with pioglitazone, and the agent also provides long-term glycemic control in type 2 diabetics. The results were reported during the American Diabetes Association (ADA) 65th Annual Meeting in San Diego, Calif.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI Helps Managed Care Identify High-Risk Patients Sooner and More Precisely | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive in Medicare Fee-For-Service Population | AMCP Nexus 2025
4
Real-World Data Drives CAR T Treatment Decisions, Reveals Benefits of Earlier Administration | AMCP Nexus 2025
5



















































